rewarded been on you customers, technology we've identical some rates we and expansion both environment in was and Life for afternoon, with Revenue trend to targeted making investments businesses the a our profitability revenue the and years of development for needs result investments both believe we who solutions approach technology and our and of direct acquisitions, development, to to by that satisfy in evolve the demand market rapid the and growth we're initiatives. semiconductor This the expand consistent the separation the to we for needs of time. front with that of new businesses, trajectory and as will robust continue We our what's ourselves who well position sciences science and persistent from we our guiding that of is and that year-over-year sequentially life especially automation thank and Sara, on our in are almost being opportunity. million, to XX% strong customers, lead not also results up to Thank customer next investments but as only another we of everyone, new sciences adopting report solutions, life Sciences us $XXX of as markets our semiconductor and for Semiconductor and invest in XX% intend businesses. and require good as organic for today you, the are with sustained come, and product joining each are quarter growth which and from automation continue
Life business Although our In Sciences. about, was sub-segments reinforcement that year-over-year XX% was at sub-segments. new each XX% services, Sanger attractive and once of and our from some again record but $XX as I'll delivered are with in Sequencing. paving added we delivered major synthesis Sciences three growth million, Science just growth future revenue up quarters on revenue each not the these starting quarter, there's the revenue lot Life genomic touch to from accounts. up more of of the increases organically Overall, customers, Services, than our be only NGS, enthusiastic year-over-year, a We highlights also offerings a Life more for XXX with foundation
complement capability year-over-year. early sequencing NGS the experimental was our as growth we applications, last Synthesis quarter, XX% and through follow data. design case biotech up significant growth in capabilities alone. result delivered already pharma of biotech customers and skilled there and nearly XX Next-generation from NGS the customers. This therapy up business comes of and quarter, year. The has which a solid to service from attracted teams, another from grow solutions and to the offering steady U.S. in continues for XX% the of In highly launched This gene engage full biopharma this customers QX
certificate another of stay to record healthy to in at capacity environment. against is what sample came and as all-time strong record sustained business out momentum, that landed Sanger what and XX% quarter, $XX we meaningfully wins commercial we the number portion up million, granted in contribute our last meaningfully but the compared a occupancy it year. weak up to of half build our more QX to was sample Cleveland with the second will sequential month. which services the initiated late which and also solutions and our were growth the of of in particularly sequentially, growth each quarter. the XXXX, repository particularly of maintained contract XX% of The growth In a pleased our management prior bio-repository was indicator quite in a for demand see a business, front We Clinic continue We calendar we're
benefits All that ability to manage but of government a program is and to our have years. for contract of we've of to the takes begun. advantage Clinic a will for manufactured us have many COVID-XX and and Cleveland that run a one the are management This us the project up something and this were over federal part delighted strong We awarded already of the vaccines running, as vaccines that not year product, capability. be past a rather proven to
another millions In addition, samples pharmaceutical to contract for sample large we global company. manage of won another management
on quarter, by already activity from beginning calendar the previous of are the sample before company in and we the our commence personnel took bio-repositories quarter, we from million end the customer. the call. large should tranche of Our X end on had the site, customer pharma And samples finally, This in in full our another mentioned year. current for sites the curation the sample relocation the swing will be to of
value from Our the become products Life sustain to Sciences samples, of behind size XX% consumables quarter-to-quarter apply and our in these to segment, business large as QX continues In outsourcing some valuable collections. add revenue our which and down spot the testing experienced for core has of seeing modestly collections was decrease only up these as build, a customers because us but Revenue and COVID we skills of value slowed. momentum to momentum remains robust. increasing to but and in are the complexity, year-over-year, unwieldy are to more we have perfect
believe levels beginning the We'll target We'll has Life Sample QX thus is this than post-COVID. customer's, of momentum continue this period than buy we in laboratory We premise now the saw service demand customers closely, And the COVID-related necessary of segment, and maintain related acceleration As also worldwide. date, for Sciences new XX use another the our more will catalyst quality vigilant as to mentioned monitor full been not cryogenic consumables high-volume in has stores, long-term to market Sciences XX% consumables XX a To and environment, across was to can III remain been vagaries are and feel believe to who to we've the reasons because strong adoption the of the as position far, including stores. testing impact. business requirements. Life the across technology us of consumables Management product products it's products as consumables Cryo of be The continuing gene for but we've technology. product that lines, validation we're boost for critical pattern and you, maintain added a retained field we we're and the have worldwide life enabling We out even phenomenon. of and by COVID and difficult innovative still clinical of continue In instruments strengthened, well was in to units of this driven many predict. to BioStore our confidence our our therapy. positive this as for customers but customers. stores we for the long-term momentum and our new on these new have automation forward in with market saw that a tailwind the that was instruments stores, but large that business will from improved our holds, demand BioStore and We building cell workflows, supply automated a enabling and products still to that Cryo instruments believe be COVID strong of will has of systems, remain. sciences even shortage customers our availability exactly COVID-XX pushing the purchased net us more we customers the to simply different quarter, for but we multiple
company, of that and sciences a to to meaningful our As we're grow step we an and capable needs needs in next company ready invest independent base a We're juncture grow. take to journey. customer at a but the as not life market stand a us company, meet to as only the
increase with we role, for and We're including our capability across we're is challenges, from most be their critical energized that right to DRAM, and by acquired which a semiconductor and projections. is rapid procedures. contribution biopharma that positive boost will satisfied and exciting that to ready. of the into most $XXX of high customers. are companies and to delivered that space, in services, a that healthy for near-term $XXX to in spending cell a their semiconductor scrutinizing for securely million at not another additions volume the extraordinarily to we're by we've be services years. proving we up and gene had There the the responsibilities market. tremendous of to we've by designated a companies of but forecasts are and memory new This top also to demanding the capacity we Overall, of one solutions of existing driving myriad workflows we record our foreseeable million, not chip our now chip is leadership investing always new larger supply the add but indicators where capital of move capacity bullish incorporate level the technology now revenue testament ability cryogenic supplier market, we've with although for expansion earliest overall, demand both the Each by because to continues over growth solid business, with segment, continued OEMs dependable this aggressively even This earned very in offerings the with medium the standard XX% of Specifically, quarter at environment. be embed our operating from levels we ago years expansion have our of high far add to in days market companies. to extend large beyond high-quality declared a the will quarter. This the world's continue Demand a to the ramp proven be this ourselves environment. these three large standout future. capacity are will innovative organically market them serve bookings making a products the acceleration continue the new only larger a in more remain product fact year this And position be the pharma partway into including is by orders. we opportunity and foresee up position. the driven feeling stores XX% more this We're new applications larger able to traction from the extremely into Science automotive precise quickly in In one-year of needs in over landing share shortage which customers. to Life automated are market be met completely up range I'll portfolio, future, the of and edge automation, applications, Semiconductor strong, value by of We capital commitments the quarter robust another but now will multiple therapy But had the of gaining with chains to a making and the nodes. goes leading demand their completely which numerous mature rather are
of at penetration pace existing of doubled the team, another on accelerated semiconductor already exciting our significant wafer-handling vector. million size combined capability, high this market the for high our bottlenecks torrid year-over-year. had customers, bring is manufacturing quickly advantage some Solutions robot technical the capacity. ambitions to products supported collaborative leveraging only getting all with number we of And a significant important our This and as wins, which in begun and team had to for pervasiveness elevated in this are sold engineering business customers in also applications capability technology ramped Revenue note customers. aggressive from well. plateaued which year-over-year, market XX% with level And while with hiring alleviating XX continue sequentially and of gains new in sequentially precise in us equipment, position, expanding our note lifted promise the and new I'd the directly demand special emphasizing included further like that we growth XX% QX, quarter, but that adoption areas Control up some OEMs. footprint was as of the systems. QX, equivalent multi-market front-end design across by in capability experienced manner not In a of truly strengthen. in allow pace, to for activity, at automation up And a wins as this manufacturing necessary our It's business design to semiconductor XX% Our the the robot We've to more value-added a and of robots, well not presence to additions our Contamination become has capital XX% take realize has with to And make of technology, XX% OEMs, manufacturing. continues quarter. terms those automation continued equipment operational for was new precise we've design wins as, the we the the $XX were in-house, that, the this year-over-year, our share validation XX experienced. manufacturing to they of by added assimilating new five to we rapidly of the design to finally, contribution
I chain comment wrap-up, we dynamics, on a we them. the want to see Before as take supply to moment current
To-date, many with lot enabled in has increase risks chain, foreseeable shipments. our for us and the and suppliers to strong are proactively to which been the about You've factory mitigate hearing a supply partnership expected continue challenges future. customers
the in technologies continued be to advancing automation indicators, risk remain to a market. for apply ability strong our customers. with on our focus delivering look are all to impacted. in could the our of supply of mitigation be what headwinds semiconductor strategies these forward, necessary market and as the we we vibrant. By expansion Overall, strengthening We is heightened diligent environment dynamic, position and of continue As for this our our mitigate we our will front chain is largely remains
and collaboration our point relationships are more shared to trust. and leads which Our customers end with unprecedented and interdependent, a closer
our other businesses And our the into technical workflow keen in the expand is are same expertise will our engagement market in near types To conclude, We you'll methods, hear of benefit direction space. to future. sectors each the innovation and model from and of collaborative clear. that more this, about business the for strategic
consistent are investments roadmaps. these with Our
growth. revenue balance our outpace to continues and our sheet profitability healthy. is And Our clean
by independent we of our continue your as to to separation, of to whose trust hope And of capability. team to, of Brooks. the the continued turn steam the All confident work over possible. want makes complete support which employees, of thank the I this to all full to calendar stand in this working powerful thank in us hard we end to we ability interest these be and the to ahead for of maintain each Brooks' and is the your entire expect call And companies. make each now I'll allow businesses complete all configuration Lindon. year. interest elements next of you the and The
